RxSight, Inc. (NASDAQ:RXST) Director Acquires $504,106.07 in Stock

RxSight, Inc. (NASDAQ:RXST) Director Jesse Anderson Corley purchased 11,111 shares of the stock in a transaction on Tuesday, November 12th. The shares were purchased at an average price of $45.37 per share, with a total value of $504,106.07. Following the acquisition, the director now directly owns 468,571 shares in the company, valued at $21,259,066.27. This represents a 2.43 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

RxSight Price Performance

Shares of NASDAQ RXST traded up $2.04 during trading on Friday, hitting $46.20. 61,642 shares of the company were exchanged, compared to its average volume of 487,675. The firm’s fifty day moving average price is $50.48 and its 200 day moving average price is $53.33. RxSight, Inc. has a 1 year low of $27.07 and a 1 year high of $66.54. The company has a market cap of $1.86 billion, a price-to-earnings ratio of -53.20 and a beta of 1.19.

Institutional Investors Weigh In On RxSight

Institutional investors and hedge funds have recently modified their holdings of the company. Point72 Hong Kong Ltd purchased a new stake in RxSight during the third quarter worth $34,000. Wasatch Advisors LP raised its position in RxSight by 47.8% during the third quarter. Wasatch Advisors LP now owns 206,740 shares of the company’s stock worth $10,219,000 after acquiring an additional 66,887 shares during the last quarter. PDT Partners LLC purchased a new stake in shares of RxSight in the third quarter valued at about $896,000. Walleye Capital LLC grew its position in shares of RxSight by 620.2% in the third quarter. Walleye Capital LLC now owns 129,687 shares of the company’s stock valued at $6,410,000 after purchasing an additional 111,681 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of RxSight by 8.3% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 68,818 shares of the company’s stock worth $3,402,000 after purchasing an additional 5,266 shares in the last quarter. Institutional investors and hedge funds own 78.78% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on RXST shares. Jefferies Financial Group started coverage on shares of RxSight in a research report on Tuesday, October 29th. They set a “buy” rating and a $72.00 price objective for the company. Needham & Company LLC reaffirmed a “buy” rating and set a $66.00 price objective on shares of RxSight in a research report on Friday, September 13th. Stifel Nicolaus decreased their target price on RxSight from $70.00 to $65.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. Oppenheimer dropped their price target on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 6th. Finally, Wells Fargo & Company lowered their target price on shares of RxSight from $68.00 to $54.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, RxSight has an average rating of “Buy” and a consensus price target of $61.63.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.